C3.ai Digital Transformation Institute Announces AI for Energy and Climate Security Grantees
C3.ai Digital Transformation Institute (C3.ai DTI) today announced the second round of C3.ai DTI awards, focused on using artificial intelligence (AI) techniques and digital transformation to advance energy efficiency and lead the way to a lower-carbon, higher-efficiency economy that will ensure energy and climate security.
C3.ai DTI issued this call for proposals in February 2021, and received 52 submissions. A rigorous peer review process led to 21 awards for research proposals to improve resilience, sustainability, and efficiency through such measures as carbon sequestration, carbon markets, hydrocarbon production, distributed renewables, and cybersecurity, among other topics.
The Institute awarded a total of $4.4 million in cash from this call for proposals, the second call the Institute has released since the organization’s launch in March 2020. In addition to cash awards, research teams gain access to up to $2 million in Azure Cloud computing resources, up to 800,000 supercomputing node hours on the Blue Waters petascale supercomputer at the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign, up to 25 million computing hours on supercomputers at Lawrence Berkeley National Laboratory’s National Energy Research Scientific Computing Center (NERSC), and free, unlimited access to the C3 AI® Suite hosted on the Microsoft Azure Cloud.
“The world’s energy infrastructure will need to undergo radical changes to address the impact of global energy generation,” said Thomas M. Siebel, chairman and CEO of C3 AI. “In the face of this crisis, the Institute is proud to bring together the best and brightest minds and provide direction and leadership to support objective analysis and AI-based, data-driven science for climate security.”
“Pursuing a sustainable future via advances in science and engineering is absolutely critical,” said Eric Horvitz, Chief Scientific Officer at Microsoft. “We’re deeply enthusiastic to join with the C3.ai Digital Transformation Institute to support frontier research on energy and climate at leading universities.”
The 21 projects were each awarded $100,000 to $250,000, for an initial period of one year, in one of nine categories, as listed below by project title, principal investigator, and affiliation.
- Sustainability - Applying AI, machine learning, and advanced analytics to support sustainability initiatives for energy consumption and greenhouse gas emissions:
- Learning in Routing Games for Sustainable Electromobility (Henrik Sandberg, KTH Royal Institute of Technology)
- AI-Driven Materials Discovery Framework for Energy-Efficient and Sustainable Electrochemical Separations (Xiao Su, University of Illinois Urbana-Champaign)
- AI for Carbon Sequestration -Applying AI/ML techniques to increase the scale and reduce costs of carbon sequestration:
- Optimization of Agricultural Management for Soil Carbon Sequestration Using Deep Reinforcement Learning and Large-Scale Simulations (Naira Hovakimyan, University of Illinois at Urbana-Champaign)
- Affordable Gigaton-Scale Carbon Sequestration: Navigating Autonomous Seaweed Growth Platforms by Leveraging Complex Ocean Currents and Machine Learning (Claire Tomlin, University of California, Berkeley)
- AI for Advanced Energy and Carbon Markets - Enabling dynamic, automated, and real-time pricing of energy-generation sources:
- Quantifying Carbon Credit Over the U.S. Midwestern Cropland Using AI-Based Data-Model Fusion (Kaiyu Guan, University of Illinois at Urbana-Champaign)
- The Role of Interconnectivity and Strategic Behavior in Electric Power System Reliability (Ali Hortacsu, University of Chicago)
- Cybersecurity of Power and Energy Infrastructure - Leveraging AI/ML techniques to improve the cybersecurity of critical power and energy assets, along with smart connected factories and homes:
- Private Cyber-Secure Data-Driven Control of Distributed Energy Resources (Subhonmesh Bose, University of Illinois at Urbana-Champaign)
- Cyberattacks and Anomalies for Power Systems: Defense Mechanism and Grid Fortification via Machine Learning Techniques (Javad Lavaei, University of California, Berkeley)
- A Joint ML+Physics-Driven Approach for Cyber-Attack Resilience in Grid Energy Management (Amritanshu Pandey, Carnegie Mellon University)
- Smart Grid Analytics - Applying AI and other analytic approaches to improve the efficiency and effectiveness of grid transmission and distribution operations:
- Scalable Data-Driven Voltage Control of Ultra-Large-Scale Power Networks (Alejandro Dominguez-Garcia, University of Illinois at Urbana-Champaign)
- Offline Reinforcement Learning for Energy-Efficient Power Grids (Sergey Levine, University of California, Berkeley)
- Distributed Energy Resource Management - Applying AI to increase the penetration and use of distributed renewables:
- Machine Learning for Power Electronics-Enabled Power Systems: A Unified ML Platform for Power Electronics, Power Systems, and Data Science (Minjie Chen, Princeton University)
- Sharing Mobile Energy Storage: Platforms and Learning Algorithms (Kameshwar Poolla, University of California, Berkeley)
- Data-Driven Control and Coordination of Smart Converters for Sustainable Power System Using Deep Reinforcement Learning (Qianwen Xu, KTH Royal Institute of Technology)
- AI for Improved Natural Catastrophe Risk Assessment -Applying AI to improve modeling of natural catastrophe risks from future weather-related events (e.g., tropical storms, wildfires, and floods):
- AI for Natural Catastrophes: Tropical Cyclone Modeling and Enabling the Resilience Paradigm (Arindam Banerjee, University of Illinois at Urbana-Champaign)
- Multi-Scale Analysis for Improved Risk Assessment of Wildfires Facilitated by Data and Computation (Marta Gonzalez, University of California, Berkeley)
- Resilient Energy Systems - Addressing how the use of AI/ML techniques and markets for energy and carbon introduce new vulnerabilities:
- A Learning-Based Influence Model Approach to Cascading Failure Prediction (Eytan Modiano, Massachusetts Institute of Technology)
- Reinforcement Learning for a Resilient Electric Power System (Alberto Sangiovanni-Vincentelli, University of California, Berkeley)
- AI for Improved Climate Change Modeling -Use of AI/ML to address climate change modeling and adaptation:
- Machine Learning to Reduce Uncertainty in the Effects of Fires on Climate (Hamish Gordon, Carnegie Mellon University)
- AI-Based Prediction of Urban Climate and Its Impact on Built Environments (Wei Liu, KTH Royal Institute of Technology)
- Interpretable Machine Learning Models to Improve Forecasting of Extreme-Weather-Causing Tropical Monster Storms (Da Yang, Lawrence Berkeley National Laboratory)
“From wildfires to rising seas to monster storms crippling our energy systems, increasingly extreme weather clearly represents a severe threat to our economy, infrastructure, and national security,” said S. Shankar Sastry, C3.ai DTI Co-Director and Thomas M. Siebel Professor of Computer Science at the University of California, Berkeley.“Improving climate resilience will require profound changes powered by a new era of technology like those C3.ai DTI is supporting today.”
“A number of energy companies and utilities have used enterprise AI to transform their operations, but as we can see, there’s an even greater need for resilience to cyberattacks and large environmental disruptions,” said R. Srikant, C3.ai DTI Co-Director and Fredric G. and Elizabeth H. Nearing Endowed Professor of Electrical and Computer Engineering at the University of Illinois at Urbana-Champaign. “These projects are designed with those goals in mind.”
C3.ai DTI selects research proposals that inspire cooperative research and advance machine learning and other AI subdisciplines. Projects are peer-reviewed on the basis of scientific merit, prior accomplishments of the principal investigator and co-principal investigators, the use of AI, machine learning, data analytics, and cloud computing in the research project, and the suitability for testing the methods at scale. Visit C3DTI.ai to learn more about the Institute’s programs, award opportunities, and selected research proposals.
About C3.ai Digital Transformation Institute
Established in March 2020 by C3 AI, Microsoft, and leading universities, the C3.ai Digital Transformation Institute is a research consortium dedicated to accelerating the benefits of artificial intelligence for business, government, and society. The Institute engages the world’s leading scientists to conduct research and train practitioners in the new Science of Digital Transformation – operating at the intersection of artificial intelligence, machine learning, cloud computing, internet of things, big data analytics, organizational behavior, public policy, and ethics.
The ten C3.ai Digital Transformation Institute consortium member universities and laboratories are: University of California, Berkeley, University of Illinois at Urbana-Champaign, Carnegie Mellon University, KTH Royal Institute of Technology, Lawrence Berkeley National Laboratory, Massachusetts Institute of Technology, National Center for Supercomputing Applications at University of Illinois at Urbana-Champaign, Princeton University, Stanford University, and University of Chicago. Additional industry partners include AstraZeneca, Baker Hughes, and Shell.
To support the Institute, C3 AI is providing the Institute $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million of in-kind support, including use of the C3 AI® Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
C3.ai DTI Contact
Communications Manager, C3.ai DTI @ Berkeley
C3 AI Public Relations
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release
Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),
New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an
Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release
The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,
Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release
Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom